Dermavant Appoints Chris Chapman as Chief Commercial Officer
January 22, 2020 08:00 ET
|
Dermavant Sciences, Inc.
Over 20 years of leadership experience in the biopharmaceutical industryFormer Vice President and General Manager, U.S. Prescription Business for GaldermaFormer Head of Pfizer’s U.S. Pharmaceutical...
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
January 15, 2020 02:39 ET
|
Dermavant Sciences, Inc.
JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan Dermavant to receive an upfront payment of $60 million,...
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
December 03, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020 BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 ...
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
June 05, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Top-line data is anticipated in the first half of 2020If PSOARING trials are successful, a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA) is anticipated in 2021 ...
Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
May 15, 2019 08:00 ET
|
Dermavant Sciences, Inc.
LONDON, May 15, 2019 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to...
Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
March 27, 2019 07:00 ET
|
Dermavant Sciences, Inc.
Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller...
Dermavant Sciences to Present Data on Tapinarof for Psoriasis and Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting
February 21, 2019 07:00 ET
|
Dermavant Sciences, Inc.
Dermavant plans to initiate Phase 3 clinical program evaluating tapinarof for the treatment of psoriasis in the first half of 2019 BASEL, Switzerland and PHOENIX, Feb. 21, 2019 (GLOBE NEWSWIRE) --...
Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer
January 02, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programsDermavant plans to initiate Phase 3...
Dermavant Sciences to Present New Data on Cerdulatinib for Atopic Dermatitis and Vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
December 06, 2018 07:00 ET
|
Dermavant Sciences, Inc.
BASEL, Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the company will present new data on cerdulatinib...
Dermavant Sciences to Present Tapinarof Phase 2b Data on Patient-Reported Outcomes for Psoriasis and Atopic Dermatitis at the Fall Clinical Dermatology Conference
October 11, 2018 08:00 ET
|
Dermavant Sciences, Inc.
BASEL, Switzerland, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that two abstracts containing Phase 2b data on...